This page shows you your search results in order of relevance. This is page number 8.

Order by Relevance | Date

Total 290035 results found since Jan 2013.

Coordinated targeting of CK2 and KIT in gastrointestinal stromal tumours
British Journal of Cancer, Published online: 28 November 2019; doi:10.1038/s41416-019-0657-5Coordinated targeting of CK2 and KIT in gastrointestinal stromal tumours
Source: British Journal of Cancer - November 27, 2019 Category: Cancer & Oncology Authors: Mengyuan Huang Wenyu Yang Jiaqing Zhu Adri án Mariño-Enríquez Chennianci Zhu Jiaming Chen Yuehong Wu Yanping Quan Haibo Qiu Xuhui Li Li Chai Jonathan A. Fletcher Wen-Bin Ou Source Type: research

Safety and efficiency of endoscopic resection versus laparoscopic resection in gastric gastrointestinal stromal tumours: A systematic review and meta-analysis
Publication date: Available online 13 December 2019Source: European Journal of Surgical OncologyAuthor(s): Chao Wang, Zhidong Gao, Kai Shen, Jian Cao, Zhanlong Shen, Kewei Jiang, Shan Wang, Yingjiang YeAbstractThe application of endoscopic resection (ER) in gastric gastrointestinal stromal tumours (GIST) is controversial. We carried out a meta-analysis to compare the safety and efficiency of ER with laparoscopic resection (LR) in patients with gastric GISTs. We searched PubMed to identify studies comparing ER with LR in GIST. The outcomes focused on two areas: safety, including operation time, blood loss, length of hospita...
Source: European Journal of Surgical Oncology (EJSO) - December 14, 2019 Category: Surgery Source Type: research

TAS-116 inhibits oncogenic KIT signalling on the Golgi in both imatinib-naïve and imatinib-resistant gastrointestinal stromal tumours
British Journal of Cancer, Published online: 20 December 2019; doi:10.1038/s41416-019-0688-yTAS-116 inhibits oncogenic KIT signalling on the Golgi in both imatinib-naïve and imatinib-resistant gastrointestinal stromal tumours
Source: British Journal of Cancer - December 19, 2019 Category: Cancer & Oncology Authors: Yurina Saito Tsuyoshi Takahashi Yuuki Obata Toshirou Nishida Shuichi Ohkubo Fumio Nakagawa Satoshi Serada Minoru Fujimoto Tomoharu Ohkawara Takahiko Nishigaki Takahito Sugase Masahiro Koh Tomo Ishida Koji Tanaka Yasuhiro Miyazaki Tomoki Makino Yukinori Ku Source Type: research

Prognostic significance of preoperative plasma fibrinogen levels in primary gastrointestinal stromal tumours: a retrospective cohort study
ConclusionsOur results suggest that high preoperative plasma Fib levels may indicate a poor prognosis in patients with primary GISTs. As a cost-effective biomarker, preoperative assessment of plasma Fib levels may help to further risk stratify patients with mNIH high-risk GISTs and instruct the application of targeted therapy.
Source: International Journal of Clinical Oncology - June 22, 2020 Category: Cancer & Oncology Source Type: research

Ripretinib for advanced gastrointestinal stromal tumours
Nature Reviews Gastroenterology & Hepatology, Published online: 25 June 2020; doi:10.1038/s41575-020-0336-2Ripretinib for advanced gastrointestinal stromal tumours
Source: Nature Reviews Gastroenterology and Hepatology - June 24, 2020 Category: Gastroenterology Authors: Katrina Ray Source Type: research

Systemic therapy of advanced/metastatic gastrointestinal stromal tumours: an update on progress beyond imatinib, sunitinib and regorafenib.
Authors: Mohammadi M, Gelderblom H Abstract Introduction Discovery of oncogenic mutations in the KIT and PDGFRA tyrosine kinase receptor was a crucial step for development of tyrosine kinase inhibitors (TKI's). Since then, GIST became a model for development of molecular targeted therapy, which led to dramatically improved median overall survival of advanced GIST . Still further progress is needed after third line or for TKI resistant mutations. Areas covered In this review, after a brief introduction of imatinib, sunitinib an regorafenib an overview of TKI's that were evaluated beyond these drugs is provided, with...
Source: Expert Opinion on Investigational Drugs - December 3, 2020 Category: Drugs & Pharmacology Tags: Expert Opin Investig Drugs Source Type: research

Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial
We present an updated analysis of avapritinib efficacy and long-term safety in this patient population.
Source: European Journal of Cancer - January 16, 2021 Category: Cancer & Oncology Authors: Robin L. Jones, C ésar Serrano, Margaret von Mehren, Suzanne George, Michael C. Heinrich, Yoon-Koo Kang, Patrick Schöffski, Philippe A. Cassier, Olivier Mir, Sant P. Chawla, Ferry A.L.M. Eskens, Piotr Rutkowski, William D. Tap, Teresa Zhou, Maria Roche, Tags: Original Research Source Type: research

Surgical Resection Is Still Better Than Endoscopic Resection for Patients With 2-5 cm Gastric Gastrointestinal Stromal Tumours: A Propensity Score Matching Analysis
ConclusionsER might be comparable to SR for the treatment of 2-3 cm gastric GISTs. SR is still considered the standard treatment for 3-5 cm gastric GISTs, while the intraoperative and postoperative information of ER should be recorded in detail and closely evaluated. Surgical resection is recommended if the tumour has a high mitotic index or mucosal ulceration.
Source: Frontiers in Oncology - September 15, 2021 Category: Cancer & Oncology Source Type: research

Targeted therapy for drug-tolerant persister cells after imatinib treatment for gastrointestinal stromal tumours
British Journal of Cancer, Published online: 05 October 2021; doi:10.1038/s41416-021-01566-9Targeted therapy for drug-tolerant persister cells after imatinib treatment for gastrointestinal stromal tumours
Source: British Journal of Cancer - October 5, 2021 Category: Cancer & Oncology Authors: Tomo Ishida Tsuyoshi Takahashi Yukinori Kurokawa Toshirou Nishida Seiichi Hirota Satoshi Serada Minoru Fujimoto Tetsuji Naka Ryugo Teranishi Takuro Saito Kotaro Yamashita Koji Tanaka Kazuyoshi Yamamoto Tomoki Makino Makoto Yamasaki Kiyokazu Nakajima Hidet Source Type: research

The KDM6A-SPARCL1 axis blocks metastasis and regulates the tumour microenvironment of gastrointestinal stromal tumours by inhibiting the nuclear translocation of p65
British Journal of Cancer, Published online: 08 February 2022; doi:10.1038/s41416-022-01728-3The KDM6A-SPARCL1 axis blocks metastasis and regulates the tumour microenvironment of gastrointestinal stromal tumours by inhibiting the nuclear translocation of p65
Source: British Journal of Cancer - February 8, 2022 Category: Cancer & Oncology Authors: Chaoyong Shen Luyin Han Baike Liu Guixiang Zhang Zhaolun Cai Xiaonan Yin Yuan Yin Zhixin Chen Bo Zhang Source Type: research

Counting mitoses in gastrointestinal stromal tumours (GISTs): variable practices in the real-world setting and their clinical implications
In conclusion, this study demonstrates that MC is still frequently performed on 50 HPF, with area sizes exceeding the specified 5 mm2 by far.
Source: Virchows Archiv - November 23, 2022 Category: Pathology Source Type: research

Prognostic and clinicopathological significance of the Prognostic Nutritional Index in patients with gastrointestinal stromal tumours undergoing surgery: a meta-analysis
Conclusions Patients with GISTs and a lower PNI had inferior RFS and OS. Patients with GISTs and a low PNI may have a higher risk of tumour recurrence.
Source: BMJ Open - December 1, 2022 Category: General Medicine Authors: Kang, N., Gu, H., Ni, Y., Wei, X., Zheng, S. Tags: Open access, Gastroenterology and hepatology Source Type: research

RWD158 A Systematic Literature Review (SLR) of Clinical Practice Guidelines (CPGS) and Real-World Treatment Patterns in Metastatic Gastrointestinal Stromal Tumours (MGISTS) in Europe
This systematic literature review aimed to identify treatment recommendations based on clinical practice guidelines (CPGs) and to understand real-world patterns of care for metastatic gastrointestinal stromal tumours (mGISTs).
Source: Value in Health - December 1, 2022 Category: International Medicine & Public Health Authors: R Mittal, T Aggarwal, R Verma, A Ahuja Source Type: research

Spectrum and surgical outcomes of gastrointestinal stromal tumours
CONCLUSION: Whilst the numbers were small, certain trends were observed. Surgery in combination with imatinib offers survival benefit in patients undergoing R0, R1, R2, liver metastases and multivisceral resections.PMID:36477053 | DOI:10.17159/2078-5151/SAJS3721
Source: South African Journal of Surgery - December 8, 2022 Category: Surgery Authors: M S A Sithole F G Madela T N Buthelezi-Zulu T Lusu K Mody N E Nyakale V Pillay B P Hadebe F Anderson Source Type: research